LONDON, ONTARIO June 12, 2020 — OB Pharmaceuticals has been granted patent US 10,618,870 from the U.S. Patent and Trademark Office (USPTO) for its first family of new chemical entities (NCEs) relating to compounds and pharmaceutical compositions for reducing the severity of convulsant activity, or epileptic seizures. In addition, these compounds have shown initial effectiveness in preclinical models of pain as covered in the original filing.
Additionally, the company was recently granted another patent US 10,556,853 for its second chemical family of compounds for utility as a method for reducing the severity of convulsant activity for one set of its structural classes. The second structural class is under review currently for the same, and requisite continuations and divisionals have been filed for pharmaceutical composition. Based on a prior “green light” PCT examination outcome of this second patent family, we believe the U.S. allowances will be forthcoming.
Both patent families have entered national phase reviews globally.
About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.